James A. Datin
Jim Datin is Executive Vice President and Managing Director at Safeguard Scientifics, Inc. (NYSE: SFE), a provider of growth capital and operational support for entrepreneurial and innovative life sciences and technology companies. At Safeguard, Jim applies his more than 25 years of experience to drive Safeguard’s partnership opportunities in both life sciences and technology, specifically targeting molecular and point-of-care diagnostics, medical devices, regenerative medicine, specialty pharmaceuticals and selected healthcare services; and Internet / New Media, Financial Services IT, Healthcare IT and selected business services, respectively.
Over the course of his career, Jim has completed approximately 50 transactions including venture investments, buyouts, acquisitions, mergers, IPOs, licensing and partnership agreements. He has been a successful CEO, raised capital for entrepreneurs to grow companies, and has turned around troubled companies throughout the United States, Europe and Asia.
Prior to Safeguard, Jim was CEO of Touchpoint Solutions; Group President of Dendrite International; Group Director, Corporate Business Strategy and Planning at GlaxoSmithKline; CEO of Isuta Holdings Berhad; and Director, International Business at Baxter/Merck KGaA.
Jim is a former board member of Intralinks, where he chaired the audit committee and filed the company’s SEC Form S-1 for its initial public offering. The company was acquired by TA & Associates, a large private holding firm, for more than $430 million, representing a 6x return to investors.
Jim currently is a member of the board for Safeguard’s partner companies NovaSom and Putney. In addition, Jim is on the Executive Board for Celerant Consulting; the Life Science Investment Advisory Committee for Ben Franklin Technology Partners of Pennsylvania; the Advisory Board for Sanofi Aventis, the board for Hepatitis B Foundation; and is Vice Chairman of the board for the University City Science Center in Philadelphia. He is a NASDAQ accredited and certified board member.
EXPERIENCE
- TouchPoint Solutions, Inc. – CEO
- Dendrite International – Group President
- GlaxoSmithKline – Group Director, Corporate Business Strategy and Planning
- Isuta Holdings – CEO
- Baxter/Merck KGaA – Director, International Business
BOARD MEMBER: Safeguard Scientifics Partner Company
BOARD MEMBER: Independent Organizations
- Ben Franklin Technology Partners of Pennsylvania – Life Science Investment Advisory Committee
- Celerant Consulting – Executive Board
- Hepatitis B Foundation
- University City Science Center – Vice Chairman
EDUCATION
- BBA, Marshall University
- MBA, University of New Haven
